Background {#Sec1}
==========

The *β*-thalassemias are among the most common genetic diseases and affect millions of children throughout the world \[[@CR1]\]. Around 1.5% (80--90 million people) of the worldwide population are carriers for *β*-thalassemia, with 50,000--60,000 new *β*-thalassemia cases being born each year \[[@CR2]\]. *β*-thalassemia is most prevalent in the populations of Asia, the Indian subcontinent, the Mediterranean countries, Africa and the Middle East \[[@CR3]--[@CR5]\]. In Pakistan, *β*-thalassemia is one of the commonest inherited disorders, with a carrier frequency of 5 to 7% of the Pakistani population \[[@CR2]\]. *β*-thalassemia patients are now surviving to older ages due to the availability of blood transfusion and iron chelation. There are around 100,000 patients registered currently but the burden of disease is increasing, with 5000 to 9000 children born with the disorder annually \[[@CR6]\].

Bloodborne infections are the second commonest reason of death in *β*-thalassemia patients in Pakistan \[[@CR2]\]. Regular blood transfusions in *β*-thalassemia patients expose them to a higher risk of contracting HCV viral infection, especially if adequate viral screening of blood donors has not been undertaken. The infection risk in β-thalassemia patients acts as a marker for the risk of transfusion-transmitted infections in the general population as their exposure to blood transfusions is high. If the infection rate is low in *β*-thalassemia patients it implies that the risk for the general population will be minimal.

Hepatitis C infection is one of the most common bloodborne infections. More than 10 million individuals are living with HCV infection in Pakistan, and hence vulnerable to high morbidity and mortality \[[@CR7]\]. Pakistan is a developing country: according to the Human Development Index of the United Nations, it stands in 150th position out of 189 countries and territories \[[@CR8]\]. The health standard in Pakistan is well below the international standards to which all countries aspire. Therefore, contaminated blood transfusion is still a main risk factor for the spread of HCV. This is due to the lack of screening and the widespread use of paid blood donors \[[@CR9]\]. Several studies have been published on the prevalence of HCV in *β*-thalassemia patients in Pakistan and there is considerable variation in the prevalence reported in the individually published studies. The purpose of this study is to investigate the pooled prevalence based on the available published studies conducted on the prevalence of HCV infection in *β*-thalassemia patients, and to describe its associated risk factors in Pakistan. To our knowledge, this is the first systematic review and meta-analysis to investigate the pooled prevalence of HCV infection in *β*-thalassemia patients in the country.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A systematic literature search on PubMed, EMBASE, the Cochrane Library, Web of Sciences, Directory of Open Access Journal and Pakistani Journals Online websites was conducted by two authors (J.A.N. and S.A.) to find studies performed on the prevalence of HCV infection in *β*-thalassemia patients and published from January 1st, 1995 to May 31st 2019. Using MeSH headings, we searched for, the terms "prevalence", "epidemiology", "seroprevalence", "hepatitis C Virus", "HCV", "hepacivirus", "hep C," "thalassemia"," *β*-thalassemia", "thalassemia major", "multitransfused blood transfusion", "patients", "Pakistan", and "Pakistani", as well as variations thereof. The results were defined using the Preferred Reporting Items for Systematic and Meta-analyses (PRISMA) statement (Table [1](#Tab1){ref-type="table"}) \[[@CR10]\], and the PRISMA 2009 checklist is attached in supplementary file S1. Table 1Description and list of characteristics of the included studiesAuthorYearStudy DesignSample sizeCasesPrevalence (%)SettingProvinceSexWorking Year% Female% MaleAverage AgeTestQualityBhatti et al.\[[@CR18]\]1995NA352160.00UrbanKhyber PakhtunkhwaBothNA14.2885.716.5ELISAMediumMuhammad et al. \[[@CR19]\]2003Cross-sectional802936.25UrbanKhyber PakhtunkhwaBothJul. 1999 to Mar. 2001NANA7.5ELISAMediumShah at al. \[[@CR20]\]2005Cross-sectional25014256.80UrbanKhyber PakhtunkhwabothJan. 2000 to Jan. 200172.002810ELISAMediumHussain \[[@CR21]\]2008Cross-sectional1807541.67UrbanKhyber PakhtunkhwaBothJan. 2002 to Dec. 2003NANA6.8ELISAGoodAli et al. \[[@CR22]\]2011NA1672615.57UrbanKhyber PakhtunkhwaBothNA62.2836.7NARNAMediumKhattak et al.\[[@CR23]\]2013NA1703721.67UrbanKhyber PakhtunkhwabothJan. 2012 to Dec. 201255.2944.7110ELISAMediumKhan et al. \[[@CR24]\]2015Cross-sectional180147.77UrbanKhyber PakhtunkhwaBothJun. 2013 to Jul. 201438.8961.11NANAMediumShah et al. \[[@CR25]\]2018NA324185.56UrbanKhyber PakhtunkhwaBothOct. 2013 to Mar. 201434.5060.2315.5RNAMediumYounus et al. \[[@CR26]\]2004Cross-sectional753242.00UrbanPunjabBothJul. to Sep. 200364.00366.5ELISAGoodIqbal at el. \[[@CR27]\]2010NA1415035.46UrbanPunjabBothSep. 2008 to Aug. 200958.2041.88ELISAMediumAin et al. \[[@CR28]\]2011Cross-sectional30019565.00UrbanPunjabBothNA34.3365.6710NAMediumIqbal at el. \[[@CR29]\]2013Cross-sectional954042.11UrbanPunjabBothOct. 2009 Apr. 201060.00409.2ELISAMediumDin et al. \[[@CR30]\]2014NA954547.00BothPunjabBothJul. 2017 to Sept. 201756.8453.687ELISAGoodNazir et al. \[[@CR31]\]2014NA2008241.00UrbanPunjabBothJan. 2013 to May 201312.00888.5ELISAMediumSaeed et al. \[[@CR32]\]2015Cross-sectional26214655.73UrbanPunjabBothNov. 2011 to Apr. 201240.0759.929.26ELISAMediumSheikh et al. \[[@CR33]\]2015Cross-sectional1459968.27UrbanPunjabBothJan. 2009 to Dec. 200963.4536.559ELISAMediumKhan et al. \[[@CR34]\]2017Cross-sectional47021645.95UrbanPunjabBothMar. 2014 to Sep. 201465.9634.044.8ELISAMediumRashid et al. \[[@CR35]\]2017Cross-sectional1302720.76UrbanPunjabBothJan. 2014 to Jun. 201460.00409.7ELISAMediumRaza et al. \[[@CR36]\]2018Cross-sectional2008241.00UrbanPunjabBothJan. 2015 to Dec. 201643.005710.11ELISAGoodMujeeb et al. \[[@CR37]\]1997NA914650.54UrbanSindhBothNA39.5660.4313NAMediumAkhtar et al. \[[@CR38]\]2002Cross-sectional3417020.50UrbanSindhBothJun-91NANA5RNAGoodAkhtar et al. \[[@CR39]\]2004NA863844.20UrbanSindhBothNA31.4067.4412ELISAMediumRiaz et al. \[[@CR40]\]2011Cross-sectional793443.00UrbanSindhBothJul. 2009to Sep. 200941.7758.2312ELISAMediumAnsari et al. \[[@CR41]\]2012Cross-sectional1602113.10UrbanSindhBothJan. 2010 to Dec. 201049.3850.638.5ELISAMediumSultan et al. \[[@CR42]\]2016Cross-sectional1002727.00UrbanSindhBothJun. 2011 to Jun. 201454.004615ELISAGoodBurki at el. \[[@CR43]\]2005NA1807541.67UrbanPunjab + Khyber PakhtunkhwaBothJan. 2002 to Dec. 2003NANA6ELISAMediumKiani et al. \[[@CR44]\]2016Cross-sectional125327321.71UrbanPunjab + SindhBothJul. 2015 to Dec. 201546.2153.7910.1NAMedium

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies were included in this study if: (1) they were published in peer-reviewed journals; (2) they were conducted in Pakistan; (3) they reported on the prevalence HCV in thalassemia patients; (4) they were published in the English language.

Studies were excluded if: (1) they were in languages other than English; (2) they were case series, reviews, letters, and editorials or commentaries; (3) they did not allow the calculation of the prevalence of HCV; (4) they were duplicates (using the same data), in which case the more recently published version only was considered; (5) they related to the Pakistani community living outside Pakistan.

Data extraction {#Sec5}
---------------

After choosing the relevant articles, two reviewers (J.A.N. and S.A.) independently screened the titles and abstracts to identify articles for full-text read. The data was then extracted using a standardised data extraction template of Microsoft Office Excel 2013. Information extracted included: surname of first author, year of study, year of publication, geographic region (province), gender, study design, study setting (rural, urban or both), sample size and average age of β-thalassemia patients. Any disagreement regarding the extracted information was resolved by discussion and mutual consensus.

Evaluating the quality of the included studies {#Sec6}
----------------------------------------------

Two authors (J.A.N. and S.A.) also independently judged the methodological quality of each included study using Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies \[[@CR11]\]. Any disagreement on the quality assessment check list was resolved by discussion and consensus. We categorized the quality of each included study as 'good' if its scored at least 70% of the points available, 'medium' if it scored 50--69%, and 'poor' if its scored less than 50%.

Statistical analysis {#Sec7}
--------------------

Statistical analyses were conducted by the software R, version 3.5.3 \[[@CR12]\], using two packages: 'meta' and 'metafor'. Random effects (DerSimonian-Laird) models were used to make point estimates and their 95% confidence intervals (95% CIs), as well as to estimate the pooled prevalence of HCV among the *β*-thalassemia patients. A process for combining prevalence in the meta-analysis of multiple studies was used and the results presented in a forest plot. The Random effect models are more conservative than fixed effect models, and have better statistical properties in the presence of heterogeneity, as the random effects model allows both within-study and between-study variances \[[@CR13], [@CR14]\]. The Freeman--Tukey Double Arcsine transformation was used to stabilise the variance prior to the calculation of the pooled estimates \[[@CR15]\]. Heterogeneity among the eligible articles was investigated with the *I*^2^ index \[[@CR16]\]. For the *I*^2^-index, values of 75, 50, and 25% were considered high, moderate, and low levels of heterogeneity, respectively. To determine the possible reasons for substantial heterogeneity, univariate meta-regression and sub group analyses were conducted by geographical location, sample size, year of study, year of publication, gender and average age of the *β*-thalassemia patients. The presence of publication bias was evaluated by visually inspecting a funnel plot and test using Egger test \[[@CR17]\], with *p*-value less than 0.05 indicating significant publication bias.

Results {#Sec8}
=======

Literature search {#Sec9}
-----------------

Initially, 229 potential studies were identified. Of these, 77 were duplicates and were removed. We screened the titles and abstracts, and eliminated 109 irrelevant studies from the meta-analysis. As a result, only 43 articles were considered for full text review. Sixteen studies were eliminated after full text review: studies with no quantitative measures of hepatitis C virus in *β*-thalassemia patients; studies that were not conducted in Pakistan; studies that provided combined HCV and hepatitis B virus prevalence; studies based on duplicated data sets or that did not meet the eligibility criteria or that failed to include relevant indicators. In the end, 27 studies fulfilled the inclusion criteria and data were extracted. Figure [1](#Fig1){ref-type="fig"} shows the study flow diagram (PRISMA) for the selection process \[[@CR10]\]. Fig. 1PRISMA 2009 flow diagram \[[@CR10]\] explaining the number of included and excluded articles in the meta-analysis on the prevalence of HCV in *β*-thalassemia patients in Pakistan

Characteristics of the included studies {#Sec10}
---------------------------------------

The characteristics of the selected articles are summarised in Table [1](#Tab1){ref-type="table"}. A cross-sectional research design was used in 17 studies, whereas ten studies did not clearly specify the research design. The articles were published between January 1995 and December 2018, while the period of participant inclusion was from June 1991 to September 2017. Three provinces of Pakistan were represented in the included studies: eight were conducted in Khyber Pakhtunkhwa \[[@CR18]--[@CR25]\], 11 were conducted in Punjab \[[@CR26]--[@CR36]\] and six were conducted in Sindh \[[@CR37]--[@CR42]\]. One study was conducted both in Punjab and Khyber Pakhtunkhwa \[[@CR43]\] while one was conducted in Punjab and Sindh \[[@CR44]\]. Most of the included studies (20 out of 27) reported (the) HCV prevalence based on the results of the ELISA (enzyme-linked immunosorbent assay) test \[[@CR17]--[@CR20], [@CR22], [@CR25], [@CR26], [@CR28]--[@CR35], [@CR40]--[@CR43]\]. Only three studies reported the confirmation of HCV infection by RNA test \[[@CR21], [@CR24], [@CR39]\]. Four studies did not explicitly mention the diagnostic methods theyused for HCV antibody reactivity testing \[[@CR23], [@CR27], [@CR36], [@CR38]\]. The sex of the patients was reported in 23 studies. The proportion of females ranged from 28.0 to 88.0%. The average age of patients varied from 4 years \[[@CR34]\] to 15.5 years \[[@CR25]\]. After reviewing the methodological quality of the studies, 6 were deemed to be of good quality, 21 of medium quality, and no article was found with poor quality. Sample size varied among studies with the smallest having a total of 35 patients \[[@CR17]\] and the largest 1253 patients \[[@CR35]\].

Prevalence of HCV in β-thalassemia patients {#Sec11}
-------------------------------------------

Table [2](#Tab2){ref-type="table"} shows the summary of statistical analyses of the prevalence of the HCV in *β*-thalassemia patients in Pakistan. The overall prevalence of HCV infection in *β*-thalassemia patients was 36.21% (95% CI: 28.98--43.75%, *I*^2^ = 97.0%; 27 studies), based on a pooled sample of 5789. A forest plot of HCV prevalence in the *β*-thalassemia patients in the three provinces of Pakistan is presented in Fig. [2](#Fig2){ref-type="fig"}. Visual inspection of the funnel plot (Fig. [3](#Fig3){ref-type="fig"}) revealed some evidence of publication bias, but it was insignificant based on Egger test (*p* = 0.1506). Table [2](#Tab2){ref-type="table"} also presents the pooled prevalence of HCV in *β*-thalassemia patients for subgroups. The pooled subgroup prevalence stratified by geographical location (province) revealed that the prevalence of HCV in *β*-thalassemia patients was highest in Punjab at 45.98% (95% CI: 38.15--53.90%; *I*^2^ = 92.3%, based on 11 studies), compared with 31.81% (95% CI: 20.27--44.59%; *I*^2^ = 92.8%; based on 6 studies) in Sindh and 28.04% (95% CI: 13.58--45.26%, *I*^2^ = 97.6%; based on 8 studies) in Khyber Pakhtunkhwa. There was no significant difference in the prevalence of HCV between male (34.71% (95% CI: 23.32--47.04%)) and female (32.31% (95% CI: 20.17--45.75%)) *β*-thalassemia patients. The prevalence of HCV in *β*-thalassemia patients increased with age: the prevalence among those below 10 years of age was 33.87% (95% CI: 18.93--50.62%, *I*^2^ = 96.2%; 9 studies) while for those above 10 years it was 51.51% (95% CI: 34.52--68.34%, *I*^2^ = 96.2%; 9 studies). There was no publication bias in any subgroup. Table 2Summary statistics from meta-analyses of prevalence studies on HCV infection among *β*-thalassemia patients residing in PakistanStudiesSampleCasesPrevalence % (95% confidence interval)*I*^2^Heterogeneity*p* value for Egger's test*p* value for differencePrevalence of HCV in *β*-thalassemia patients275789196036.2 (28.98--43.75)0.970\<  0.0010.1506**By sex**0.7978 Male12189459234.71 (23.32--47.04)0.963\<  0.00010.2923 Female12131636432.31 (20.17--45.75)0.952\<  0.00010.2304**By age**0.1460 Less than 10 years997038633.87 (18.93--50.62)0.9620.09150.4417 10 years or above950924351.51 (34.52--68.34)0.932\<  0.0010.1705**By province**0.0573 Punjab112113101445.98 (38.15--53.90)0.923\<  0.0010.1496 Sindh685723631.81 (20.27--44.59)0.928\<  0.0010.0922 Khyber Pakhtunkhwa8138636228.04 (13.58--45.26)0.976\<  0.0010.3754**By period**0.5388 1995--2004670822341.27 (28.15--55.03)0.913\< 0.00010.0050 2005--201412201782238.03 (28.13--48.45)0.956\<  0.0010.2211 2015--20189306490230.66 (18.06--44.91)0.983\<  0.0010.5755Fig. 2Forest plot of the prevalence of HCV infection among in *β*-thalassemia patients in PakistanFig. 3Funnel plot of the prevalence of HCV infection in *β*-thalassemia patients in Pakistan

The results of the univariate meta-regression analysis of the prevalence of HCV in *β*-thalassemia patients are presented in Table [3](#Tab3){ref-type="table"}. The analysis shows that only geographical region (province) had a significant effect on the prevalence of HCV in *β*-thalassemia patients with a *p*-value \< 0.1, while year of publication, year of study, sample size, proportion of males, average age of thalassemia patients had no significant effect on the observed HCV prevalence in *β*-thalassemia patients. Table 3Results of bivariate meta-regression for prevalence of HCV infection in *β*-thalassemia patients in PakistanCovariateCategoryNumber of StudiesMeta-regression Coefficient (%)*p*-valueVariance explained *R*^2^ (%)Geographical region (Province)Khyber Pakhtunkhwa8126.97Punjab110.18730.0306Sindh60.04470.6582Year of publication27−0.00980.11761.33Year of study21−0.00760.30580.00Sample size\<  100812.92\> = 10019−0.13290.1187Proportion of males23−0.00030.91890.00Average age of patients25− 0.00580.65983.41Sample size, continuous27−0.00980.11761.33

Discussion {#Sec12}
==========

The aim of this study was to summarise the available literature on the prevalence of hepatitis C virus infection in *β*-thalassemia patients and its correlated risk factors in Pakistan. The result of this meta-analysis showed that the pooled prevalence based on 27 studies was 36.21%. More than one in every three *β*-thalassemia patients in Pakistan have already been exposed to HCV infection. The pooled prevalence of HCV in *β*-thalassemia patients, as showed by this study is six times higher (36.21%) than in the general Pakistani population which is 6.2% \[[@CR45]\]. In Pakistan, many patients with *β*-thalassemia have limited access to regular and safe blood transfusions. Possible reasons for this are the lack of altruistic voluntary blood donors and the inadequate testing of blood donations for HCV. Many blood transfusion centers and hospitals have inadequate resources and kits for screening blood donations \[[@CR5]\]. The root cause of the high prevalence is predominantly the lack of adequate regulation of blood banks and monitoring to assess compliance with transfusion safety standards. It is well recognized that, with proper regulation driven by policy makers, transfusion transmitted infections are markedly reduced \[[@CR5]\]. Pakistan is a low resource country: the pooled prevalence of HCV in *β*-thalassemia patients in Pakistan is higher than that in Iran \[[@CR46]\] (19%) or Bangladesh \[[@CR47]\] (14.7%). The findings of this study should act as a major safety alert for decision and policy-makers in the Pakistani health sector.

Our data on HCV infection prevalence among the *β*-thalassemia patients covers all provinces of Pakistan except Baluchistan and Gilgit-Baltistan. Our results showed that the prevalence of HCV infection in *β*-thalassemia patients was higher in Punjab (45.98%) than in Sindh (31.81%) and Khyber Pakhtunkhwa (28.04%).

In this paper, we observed that the prevalence of HCV in *β*-thalassemia patients rises with age, increasing from 33.87% in the under 10 years age group to 51.51% in the 10 years or above age group. This effect was not statistically significant at conventional levels. We believe that age is acting as a proxy for other effects. Age is associated with cumulative exposure to blood transfusions over a life time and it is the number of blood transfusions which is associated with increased risk of HCV infection. Unfortunately, we do not have data on the number of blood transfusion patients had received. Conversely, one could look at this more positively and suggest that the frequency of testing for HCV positive blood donations has improved and hence younger patients have a lower infection rate than their older fellow patients did when they were the same age, due to safer blood donations.

Meta-regression analyses showed that there was no significant change in the prevalence of HCV in *β*-thalassemia patients over the past three decades (with both years of publication and year of study (data collection).

To our knowledge, this is the first systematic review and meta-analysis to compile current data on the prevalence of HCV infection among *β*-thalassemia patients in Pakistan. The main strengths of this study are the use of a comprehensive and a predefined literature search strategy, and the involvement of two independent reviewers in the whole review process and data extraction. No publication bias was found within our analyses which suggests that we are unlikely to have missed any potential studies that could change the results of this meta-analysis. Furthermore, the methodological quality of all included articles had a low risk of bias. As showed by meta-regression analysis, the methodological quality of the studies had no influence on pooled prevalence estimates. Three provinces of Pakistan were covered in the investigation of HCV infection prevalence in *β*-thalassemia patients. On the other hand, the findings of this study have some limitations. Firstly, the meta-regression analysis was only based on bivariate analysis. We planned to use a multivariate meta-regression model by considering all the factors simultaneously, however, it was not possible to use multivariate meta-regression analysis due to the small number of studies. A multivariate meta-regression analysis requires at least ten studies per factor to estimate the meta-regression coefficients efficiently. Second, and as is common in meta-analyses, the study estimates revealed substantial heterogeneity between the included studies, which may be due to the other sources of variation may have been missed in our analysis, such as the number of blood transfusions, some genetic factors, and type of *β*-thalassemia; but we were unable to investigate these factors due to lack of data.

Conclusions {#Sec13}
===========

The overall prevalence of HCV in *β*-thalassemia patients in Pakistan was 36.21%, but varied from province to province. The prevalence is higher than in neighboring countries such as Iran and Bangladesh. Pakistan is a developing country and lacking in resources for appropriate blood screening facilities in thalassemia centers and hospitals. Lack of robust policies on transfusion safety as well as appropriate and rigorous monitoring of blood banks to ensure compliance with policies perpetuate the risk of transfusion transmitted infection with HCV. National and regional health programs should mandate and monitor the screening procedures so as to reduce the risk of transfusion transmitted infections such as HCV in the general population in *β*-thalassemia patients.
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